Aytu Biopharma Inc reports results for the quarter ended in March - Earnings Summary

Aytu Biopharma

15/05/2024 23:16

* Aytu Biopharma Inc  AYTU.OQ  reported a quarterly adjusted
loss
of 52 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of $-1.93.  The lone analyst forecast for the quarter was for a
loss of 64 cents per share. 
    * Revenue fell 20.9% to $17.99 million from a year ago;
analysts
expected $17.35 million. 
    * Aytu Biopharma Inc's reported EPS for the quarter was a
loss
of 52 cents​.
    * The company reported a quarterly loss of $2.89 million.
    * Aytu Biopharma Inc shares had risen by 9.2% this
quarter and
gained 16.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 33.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Aytu Biopharma
Inc is $8.00 
This summary was machine generated from LSEG data May 15 at
10:16 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.64          -0.52          Beat
 Dec. 31 2023      -0.25          -0.04          Beat
 Sep. 30 2023      -0.04          -1.48          Missed
 Jun. 30 2023      -0.95          -0.59          Beat